Balyasny Asset Management
HRTX icon

Balyasny Asset Management’s Heron Therapeutics HRTX Stock Holding History

Balyasny Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,492
Closed -$25.3K – 3050
2025
Q1 		$25.3K Buy
+11,492
New +$22.3K ﹤0.01% 2716
2024
Q3 		– Sell
-26,868
Closed -$94K – 2920
2024
Q2 		$94K Buy
+26,868
New +$82.5K ﹤0.01% 2405
2023
Q1 		– Sell
-294,063
Closed -$735K – 2875
2022
Q4 		$735K Buy
294,063
+262,374
+828% +$845K ﹤0.01% 1759
2022
Q3 		$133K Sell
31,689
-471,996
-94% -$1.85M ﹤0.01% 2379
2022
Q2 		$1.41M Buy
+503,685
New +$2.02M ﹤0.01% 1604
2022
Q1 		– Sell
-602,613
Closed -$5.5M – 2627
2021
Q4 		$5.5M Buy
602,613
+121,841
+25% +$1.24M 0.02% 822
2021
Q3 		$5.14M Buy
480,772
+89,339
+23% +$1.09M 0.02% 810
2021
Q2 		$6.08M Buy
+391,433
New +$6.23M 0.03% 653
2019
Q2 		– Sell
-191,698
Closed -$4.68M – 1584
2019
Q1 		$4.68M Buy
191,698
+86,493
+82% +$2.26M 0.03% 580
2018
Q4 		$2.73M Sell
105,205
-210,249
-67% -$5.78M 0.02% 634
2018
Q3 		$9.98M Buy
+315,454
New +$11.7M 0.05% 487
2018
Q2 		– Sell
-1,632,240
Closed -$45M – 1929
2018
Q1 		$45M Buy
1,632,240
+2,359
+0.1% +$53.5K 0.19% 141
2017
Q4 		$29.5M Buy
1,629,881
+487,926
+43% +$7.96M 0.09% 293
2017
Q3 		$18.4M Sell
1,141,955
-79,448
-7% -$1.25M 0.07% 335
2017
Q2 		$16.9M Buy
1,221,403
+24,688
+2% +$358K 0.07% 371
2017
Q1 		$18M Buy
+1,196,715
New +$16.6M 0.08% 309

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management's HRTX Position: Q2 2025 in Review

Balyasny Asset Management sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 11,492 shares — an estimated $25.3K sold.

Balyasny Asset Management first reported a position in HRTX in Q1 2017 and held it in 16 quarters. The position peaked at $45M in Q1 2018. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

  • Balyasny Asset Management reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 11,492 Heron Therapeutics shares in Q2 2025, an estimated $25.3K.
  • Balyasny Asset Management first reported a position in Heron Therapeutics in Q1 2017 and held it in 16 quarters.
  • Balyasny Asset Management's Heron Therapeutics position peaked at $45M in Q1 2018.
  • 171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.